» Articles » PMID: 37874477

Genetic Alterations Landscape in Paediatric Thyroid Tumours And/or Differentiated Thyroid Cancer: Systematic Review

Overview
Publisher Springer
Specialty Endocrinology
Date 2023 Oct 24
PMID 37874477
Authors
Affiliations
Soon will be listed here.
Abstract

Differentiated thyroid cancer (DTC) is a rare disease in the paediatric population (≤ 18 years old. at diagnosis). Increasing incidence is reflected by increases in incidence for papillary thyroid carcinoma (PTC) subtypes. Compared to those of adults, despite aggressive presentation, paediatric DTC has an excellent prognosis. As for adult DTC, European and American guidelines recommend individualised management, based on the differences in clinical presentation and genetic findings. Therefore, we conducted a systematic review to identify the epidemiological landscape of all genetic alterations so far investigated in paediatric populations at diagnosis affected by thyroid tumours and/or DTC that have improved and/or informed preventive and/or curative diagnostic and prognostic clinical conduct globally. Fusions involving the gene RET followed by NTRK, ALK and BRAF, were the most prevalent rearrangements found in paediatric PTC. BRAF V600E was found at lower prevalence in paediatric (especially ≤ 10 years old) than in adults PTC. We identified TERT and RAS mutations at very low prevalence in most countries. DICER1 SNVs, while found at higher prevalence in few countries, they were found in both benign and DTC. Although the precise role of DICER1 is not fully understood, it has been hypothesised that additional genetic alterations, similar to that observed for RAS gene, might be required for the malignant transformation of these nodules. Regarding aggressiveness, fusion oncogenes may have a higher growth impact compared with BRAF V600E. We reported the shortcomings of the systematized research and outlined three key recommendations for global authors to improve and inform precision health approaches, glocally.

Citing Articles

DICER1: The Argonaute Endonuclease Family Member and Its Role in Pediatric and Youth Pathology.

Sergi C, Minervini F Biology (Basel). 2025; 14(1).

PMID: 39857323 PMC: 11761906. DOI: 10.3390/biology14010093.


Systemic treatments for radioiodine-refractory thyroid cancers.

Chen P, Yao Y, Tan H, Li J Front Endocrinol (Lausanne). 2024; 15:1346476.

PMID: 39473507 PMC: 11518755. DOI: 10.3389/fendo.2024.1346476.


Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer.

Zhang W, Lin S, Wang Z, Zhang W, Xing M J Clin Endocrinol Metab. 2024; 109(12):3166-3175.

PMID: 38735658 PMC: 11570377. DOI: 10.1210/clinem/dgae327.

References
1.
Qian Z, Jin M, Meister K, Megwalu U . Pediatric Thyroid Cancer Incidence and Mortality Trends in the United States, 1973-2013. JAMA Otolaryngol Head Neck Surg. 2019; 145(7):617-623. PMC: 6547136. DOI: 10.1001/jamaoto.2019.0898. View

2.
Hay I, Johnson T, Kaggal S, Reinalda M, Iniguez-Ariza N, Grant C . Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015). World J Surg. 2017; 42(2):329-342. DOI: 10.1007/s00268-017-4279-x. View

3.
Lee Y, Jung H, Kim H, Choi H, Kim H, Hah J . Pediatric patients with multifocal papillary thyroid cancer have higher recurrence rates than adult patients: a retrospective analysis of a large pediatric thyroid cancer cohort over 33 years. J Clin Endocrinol Metab. 2015; 100(4):1619-29. DOI: 10.1210/jc.2014-3647. View

4.
Lazar L, Lebenthal Y, Steinmetz A, Yackobovitch-Gavan M, Phillip M . Differentiated thyroid carcinoma in pediatric patients: comparison of presentation and course between pre-pubertal children and adolescents. J Pediatr. 2009; 154(5):708-14. DOI: 10.1016/j.jpeds.2008.11.059. View

5.
Alessandri A, Goddard K, Blair G, Fryer C, Schultz K . Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol. 2000; 35(1):41-6. DOI: 10.1002/1096-911x(200007)35:1<41::aid-mpo7>3.0.co;2-7. View